Researchers outlined progress in in vivo CAR therapeutic development, describing delivery strategies (viral vectors, nanoparticles), CRISPR editing needs, and assay frameworks for assessing CAR expression and function within living systems. ACROBiosystems announced reagent sets—labeled proteins, flow-cytometry panels, and high-fidelity Cas nucleases—to standardize discovery and support translation. The report emphasizes targets for improvement: precise T-cell targeting, on‑target expression, and minimized off‑target toxicity. Standardized reagents and protocols aim to speed lead selection and reduce preclinical variability as sponsors consider direct in vivo reprogramming as an alternative to costly ex vivo manufacturing.